MET and gastric cancer: MET gene amplification has been found in patients carrying gastric cancers, lung tumors, and in type 1 papillary renal cell carcinomas at a frequency around 10% [9–11], and at a lower frequency (1–5%) in hepatocellular carcinomas, ovarian tumors, melanomas and type 2 papillary renal cell carcinomas [11–14].